BSE Live
Apr 02, 16:01Prev. Close
51.28
Open Price
53.75
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Apr 02, 15:57Prev. Close
51.17
Open Price
51.17
Bid Price (Qty.)
55.53 (120)
Offer Price (Qty.)
0.00 (0)
| Key Financial Ratios of Lyka Labs (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 2.28 | -0.72 | -4.65 | 13.87 | -5.08 | |
| Diluted EPS (Rs.) | 2.28 | -0.72 | -4.65 | 13.87 | -5.08 | |
| Cash EPS (Rs.) | 4.11 | 3.03 | 0.07 | 19.27 | -2.23 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 37.81 | 30.02 | 24.90 | 15.49 | 1.54 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 37.81 | 30.02 | 24.90 | 15.49 | 1.54 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 37.74 | 32.15 | 26.26 | 57.28 | 21.70 | |
| PBDIT/Share (Rs.) | 5.67 | 4.90 | 6.21 | 34.93 | 5.80 | |
| PBIT/Share (Rs.) | 3.86 | 1.18 | 1.80 | 29.57 | 2.99 | |
| PBT/Share (Rs.) | 3.22 | -0.28 | -4.30 | 21.00 | -6.41 | |
| Net Profit/Share (Rs.) | 2.31 | -0.69 | -4.33 | 13.91 | -5.04 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 15.02 | 15.23 | 23.64 | 60.97 | 26.71 | |
| PBIT Margin (%) | 10.22 | 3.68 | 6.86 | 51.61 | 13.79 | |
| PBT Margin (%) | 8.51 | -0.87 | -16.38 | 36.65 | -29.54 | |
| Net Profit Margin (%) | 6.10 | -2.13 | -16.48 | 24.27 | -23.22 | |
| Return on Networth / Equity (%) | 6.09 | -2.28 | -17.38 | 89.79 | -327.92 | |
| Return on Capital Employed (%) | 8.56 | 2.61 | 3.71 | 73.87 | 5.09 | |
| Return on Assets (%) | 4.00 | -1.22 | -7.42 | 19.13 | -6.77 | |
| Total Debt/Equity (X) | 0.27 | 0.56 | 0.92 | 2.87 | 36.39 | |
| Asset Turnover Ratio (%) | 0.69 | 0.58 | 0.42 | 0.78 | 0.29 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.48 | 1.39 | 1.41 | 0.51 | 0.58 | |
| Quick Ratio (X) | 1.20 | 1.13 | 1.18 | 0.42 | 0.48 | |
| Inventory Turnover Ratio (X) | 12.23 | 12.90 | 3.05 | 4.32 | 2.46 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 396.90 | 401.27 | 383.67 | 501.87 | 229.21 | |
| EV/Net Operating Revenue (X) | 2.95 | 3.77 | 4.76 | 3.05 | 3.68 | |
| EV/EBITDA (X) | 19.62 | 24.76 | 20.14 | 5.01 | 13.78 | |
| MarketCap/Net Operating Revenue (X) | 2.67 | 3.30 | 3.99 | 2.37 | 1.20 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 2.67 | 3.53 | 4.20 | 8.75 | 16.93 | |
| Price/Net Operating Revenue | 2.67 | 3.30 | 3.99 | 2.37 | 1.20 | |
| Earnings Yield | 0.02 | -0.01 | -0.04 | 0.10 | -0.19 |
30.01.2026
Lyka Labs Consolidated December 2025 Net Sales at Rs 30.73 crore, down 9.08% Y-o-Y
30.01.2026
Lyka Labs Standalone December 2025 Net Sales at Rs 30.73 crore, down 6.66% Y-o-Y
19.11.2025
Lyka Labs Consolidated September 2025 Net Sales at Rs 36.66 crore, down 10.92% Y-o-Y
13.11.2025
Lyka Labs Standalone September 2025 Net Sales at Rs 32.97 crore, down 19.89% Y-o-Y
30.01.2026
Lyka Labs Consolidated December 2025 Net Sales at Rs 30.73 crore, down 9.08% Y-o-Y
30.01.2026
Lyka Labs Standalone December 2025 Net Sales at Rs 30.73 crore, down 6.66% Y-o-Y
19.11.2025
Lyka Labs Consolidated September 2025 Net Sales at Rs 36.66 crore, down 10.92% Y-o-Y
13.11.2025
Lyka Labs Standalone September 2025 Net Sales at Rs 32.97 crore, down 19.89% Y-o-Y
02.04.2026
02.04.2026
Lupin shares down 2% as arm to acquire 43.38% stake in Multicare Pharma
02.04.2026
02.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth